MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Immunocore Holdings PLC ADR

Fermé

32.9 -1.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.68

Max

33.01

Chiffres clés

By Trading Economics

Revenu

29M

5M

Ventes

9.8M

94M

BPA

-0.49

Marge bénéficiaire

5.35

Employés

493

EBITDA

13M

-3.6M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+96.52% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

73M

1.6B

Ouverture précédente

34.75

Clôture précédente

32.9

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Immunocore Holdings PLC ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juil. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 juil. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Received All Required Authorizations

4 juil. 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Agreement Was Announced on Dec. 19

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 juil. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 juil. 2025, 14:30 UTC

Acquisitions, Fusions, Rachats

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 juil. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 juil. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 juil. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 juil. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 juil. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Immunocore Holdings PLC ADR prévision

Objectif de Prix

By TipRanks

96.52% hausse

Prévisions sur 12 Mois

Moyen 64.89 USD  96.52%

Haut 100 USD

Bas 33 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

8

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

27.895 / 30.16Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.